This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cobbe, S. M. Articles by Senges, J. Search for Related Content PubMed PubMed Citation Articles by Cobbe, S. M. Articles by Senges, J.

Circulation, Vol 68, 865-871, Copyright © 1983 by American Heart Association

ARTICLES

Action of sotalol on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs in the late postmyocardial infarction phase

SM Cobbe, E Hoffman, A Ritzenhoff, J Brachmann, W Kubler and J Senges

Sotalol is a beta-adrenergic blocker that also prolongs action potential duration and myocardial refractoriness over the short term (class III effect). Its short-term antiarrhythmic effects were compared with those of metoprolol, which has neither short-term class III nor membrane-stabilizing action, on reentrant ventricular arrhythmias produced by programmed stimulation in 17 conscious dogs 3 to 8 days after myocardial infarction. Ventricular arrhythmias were prevented or significantly slowed by sotalol in 11 of 19 studies (58%) compared with in one of 14 (7%) studies with metoprolol. Sotalol prolonged refractoriness in the infarct zone, measured from an implanted "composite" electrode, by 41 +/- 45% (mean +/- SD, p less than .01), which was significantly greater than the increases it produced in effective refractory period of the normal ventricle (14.0 +/- 5.5%) or QT interval (12.5 +/- 7.8%). Metoprolol had no effect on infarct-zone refractoriness. Sotalol differentially increases refractoriness in potential reentry circuits in ischemic myocardium. Its antiarrhythmic effect in this model is not due to beta-blockade, and is presumably related to prolongation of action potential duration.

This article has been cited by other articles:

				K. D Freigang, A. Bauer, R. Becker, J. C Senges, P. Kraft, J. Brachmann, W. Kubler, and W. Schoels Differential effects of d-sotalol on normal and infarcted myocardium: an experimental study using epicardial mapping Cardiovasc Res, July 1, 1997; 35(1): 52 - 59. [Abstract] [Full Text] [PDF]

				E. Patterson, B. J. Scherlag, S. Sangiah, G. L. Garrison, K. M. Couch, K. D. Berlin, and R. Lazzara Class III Electrophysiologic Actions of Imidazole-Substituted Diheterabicyclononanes in Canine Myocardium J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 155 - 162. [Abstract] [Full Text]

				S. H. Hohnloser and R. L. Woosley Sotalol N. Engl. J. Med., July 7, 1994; 331(1): 31 - 38. [Full Text]